BioTuesdays

Category - News

Evoke Pharma
Markets

Rodman starts Evoke Pharma at buy

Rodman & Renshaw has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “buy” rating and $27 price target. The stock closed at $2.91 on Wednesday. Evoke is currently focused on advancing an intranasal...

October 1, 2015
oramed
Markets

Rodman starts Oramed at buy

Rodman & Renshaw has launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMD) with a “buy” rating and $24 price target. The stock closed at $5.47 on Wednesday. “Oramed constitutes a differentiated take on diabetes...

October 1, 2015
Cellectar Biosciences
Developments

Cellectar gets NCI grant for PDC platform

Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant. The SBIR grant provides up to $2.3-million over 2 1/2 years from the...

October 1, 2015
ANI Pharmaceuticals
Markets

Roth upgrades ANI Pharma to buy

Roth Capital Partners has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) to ”buy” from “neutral” but lowered its price target to $60 from $67. The stock closed at $43.21 on Friday. “We are upgrading shares of ANI...

September 28, 2015
Vital Therapies
Developments

Vital outlines plans for new Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...

September 28, 2015
novadaq
Developments

Novadaq unveils SPY-Q Case Manager software

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas. SPY-QCM is an image acquisition and analysis...

September 28, 2015